Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABP Abpro	$0.21 -7.8%	$0.30	$0.15 ▼ $13.00	$11.07M	-0.01	5.71 million shs	2.58 million shs
EDSA Edesa Biotech	$1.96 -2.5%	$2.28	$1.55 ▼ $5.59	$13.77M	0.55	490,386 shs	12,991 shs
IXHL Incannex Healthcare	$0.22 +7.8%	$0.49	$0.08 ▼ $3.55	$3.89M	7.67	10.29 million shs	26.68 million shs
MBRX Moleculin Biotech	$0.95 +1.2%	$0.96	$0.40 ▼ $5.12	$13.44M	1.64	1.47 million shs	103,698 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABP Abpro	-7.83%	-7.83%	-34.61%	-74.67%	+21,199,900.00%
EDSA Edesa Biotech	-2.49%	-3.45%	-17.26%	-17.65%	-57.11%
IXHL Incannex Healthcare	+7.77%	-16.27%	-63.10%	-86.48%	-91.91%
MBRX Moleculin Biotech	+1.20%	+1.17%	-7.67%	-25.70%	-80.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABP Abpro	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EDSA Edesa Biotech	2.6014 of 5 stars	3.5	5.0	0.0	0.0	0.9	1.7	0.6
IXHL Incannex Healthcare	0.4896 of 5 stars	0.0	2.0	0.0	0.0	3.0	1.7	0.0
MBRX Moleculin Biotech	2.1794 of 5 stars	3.5	2.0	0.0	0.0	2.8	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABP Abpro	3.00	Buy	$4.00	1,786.79% Upside
EDSA Edesa Biotech	3.00	Buy	$21.00	971.43% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A
MBRX Moleculin Biotech	3.00	Buy	$6.00	530.91% Upside

Current Analyst Ratings Breakdown

Latest IXHL, ABP, EDSA, and MBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/25/2025	MBRX Moleculin Biotech	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$4.00
3/24/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/13/2025	EDSA Edesa Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00
3/3/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
2/24/2025	ABP Abpro	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00

(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABP Abpro	$183K	60.49	N/A	N/A	N/A	∞
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	$0.18 per share	N/A
IXHL Incannex Healthcare	$98K	39.67	N/A	N/A	$0.05 per share	4.35
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$11.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABP Abpro	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
EDSA Edesa Biotech	-$6.17M	-$1.59	N/A	N/A	N/A	N/A	-233.69%	-124.14%	8/8/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-289.30%	-154.96%	N/A
MBRX Moleculin Biotech	-$29.77M	N/A	0.00	N/A	N/A	N/A	-157.44%	-97.16%	8/12/2025 (Estimated)

Latest IXHL, ABP, EDSA, and MBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	N/A	ABP Abpro	N/A	-$0.08	N/A	-$0.08	N/A	N/A
5/15/2025	Q3 2025	IXHL Incannex Healthcare	-$0.46	-$0.24	+$0.22	-$0.20	$0.16 million	$0.10 million
5/14/2025	Q2 2025	EDSA Edesa Biotech	-$0.30	-$0.30	N/A	-$0.30	N/A	N/A
5/13/2025	Q1 2025	MBRX Moleculin Biotech	-$0.71	-$0.69	+$0.02	-$0.69	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABP Abpro	N/A	N/A	N/A	N/A	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABP Abpro	N/A	N/A	N/A
EDSA Edesa Biotech	N/A	1.09	0.91
IXHL Incannex Healthcare	2.47	1.80	1.65
MBRX Moleculin Biotech	N/A	2.08	2.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABP Abpro	23.30%
EDSA Edesa Biotech	5.50%
IXHL Incannex Healthcare	0.43%
MBRX Moleculin Biotech	15.52%

Insider Ownership

Company	Insider Ownership
ABP Abpro	20.80%
EDSA Edesa Biotech	22.60%
IXHL Incannex Healthcare	26.53%
MBRX Moleculin Biotech	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABP Abpro	15	52.22 million	4.57 million	N/A
EDSA Edesa Biotech	20	7.02 million	2.60 million	Not Optionable
IXHL Incannex Healthcare	3	17.86 million	13.12 million	Not Optionable
MBRX Moleculin Biotech	20	14.13 million	3.86 million	Not Optionable

IXHL, ABP, EDSA, and MBRX Headlines

Recent News About These Companies

Roth Capital Has Positive Estimate for MBRX Q2 Earnings

May 18, 2025 | americanbankingnews.com

Earnings call transcript: Moleculin Biotech reports Q1 2025 updates

May 15, 2025 | uk.investing.com

MOLECULIN BIOTECH Earnings Results: $MBRX Reports Quarterly Earnings

May 15, 2025 | nasdaq.com

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | globenewswire.com

Moleculin Biotech, Inc.: Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 12, 2025 | finanznachrichten.de

Moleculin Biotech, Inc. Expands Phase 3 Trial of Annamycin for R/R AML to Nine EU Countries, Enrollment Underway

May 12, 2025 | quiverquant.com

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 12, 2025 | globenewswire.com

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

May 7, 2025 | globenewswire.com

Moleculin secures two new US patents for cancer drug Annamycin

May 6, 2025 | investing.com

Moleculin Biotech, Inc. Announces INN Approval for Annamycin as Pivotal Phase 3 Trial Advances in AML Treatment

May 6, 2025 | quiverquant.com

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

May 6, 2025 | globenewswire.com

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

May 5, 2025 | globenewswire.com

Moleculin reports Annamycin cancer drug synergy at AACR meeting

April 30, 2025 | investing.com

Moleculin Biotech Presents Promising Annamycin Data at AACR Annual Meeting 2025, Highlighting Synergistic Potential with FDA Approved Cancer Therapies

April 30, 2025 | nasdaq.com

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

April 29, 2025 | globenewswire.com

Moleculin Biotech Releases Corporate Presentation Online

April 21, 2025 | tipranks.com

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

April 17, 2025 | globenewswire.com

Moleculin Biotech begins dosing subjects in combination therapy trial for AML

April 2, 2025 | clinicaltrialsarena.com

Moleculin Biotech doses first patient in Phase 3 MIRACLE trial

April 2, 2025 | finance.yahoo.com

Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now

April 1, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL, ABP, EDSA, and MBRX Company Descriptions

Abpro NASDAQ:ABP

$0.21 -0.02 (-7.83%)

As of 05/23/2025 04:00 PM Eastern

Abpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.

Edesa Biotech NASDAQ:EDSA

$1.96 -0.05 (-2.49%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$1.99 +0.03 (+1.53%)

As of 05/23/2025 07:56 PM Eastern

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Incannex Healthcare NASDAQ:IXHL

$0.22 +0.02 (+7.77%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$0.21 -0.01 (-3.08%)

As of 05/23/2025 07:59 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Moleculin Biotech NASDAQ:MBRX

$0.95 +0.01 (+1.20%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$0.93 -0.02 (-2.21%)

As of 05/23/2025 07:29 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time